Sep 30 |
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
|
Sep 13 |
Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet
|
Sep 12 |
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
|
Sep 11 |
Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock
|
Sep 4 |
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
|
Sep 3 |
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
|
Aug 28 |
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade
|
Aug 12 |
FDA grants IND clearance for TG Therapeutics’ trial of multiple sclerosis treatment
|
Aug 9 |
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
|
Aug 1 |
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
|